The shadow of generic rivalry has consistently loomed around copyright’s iconic drug, Sildenafil, raising questions about the prospects of similar drug holdings. While initial times saw substantial returns, the patent expiration has opened the door for cheaper substitutes, possibly lowering profitability and presenting a significant danger for st